Mechanisms underlying the development of androgen-independent prostate cancer

Clinical Cancer Research

Volumn 12, Issue 6, 2006, Pages 1665-1671

  Pienta, Kenneth J ^a   Bradley, Deborah ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANDROGEN; ANDROGEN RECEPTOR; ATRASENTAN; BEVACIZUMAB; CALCITRIOL; DOCETAXEL; EPIDERMAL GROWTH FACTOR; EPOTHILONE DERIVATIVE; GENE EXPRESSION MODULATOR 231; HEAT SHOCK PROTEIN 90; INTERLEUKIN 6; KERATINOCYTE GROWTH FACTOR; MITOXANTRONE; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PREDNISONE; PROVENGE; SAMARIUM; SATRAPLATIN; SOMATOMEDIN; SORAFENIB; STRONTIUM; ZOLEDRONIC ACID;

CANCER STEM CELL; CLINICAL TRIAL; DRUG BINDING; DRUG EFFECT; DRUG INHIBITION; HUMAN; MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SURVIVAL RATE;

ANDROGENS; HUMANS; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 33645690200     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0067     Document Type: Review

References (92)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin 2005;55:10-30.
2. Huggins CB, Hodges CV. Studies on prostatic cancer. 1. The effect of castration, of estrogen and of androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
3. Huggins C. Endocrine-induced regression of cancers. Cancer Res 1967;27:1925-30.
4. Saitoh H, Hida M, Shimbo T, et al. Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. Cancer 1984;54:3078-84.
5. Grayhack JT, Keeler TC, Kozlowski JM. Carcinoma of the prostate. Hormonal therapy. Cancer 1987;60:589-601.
6. Haranda M, Iida M, Yamaguchi M, et al. Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases. In: Prostate cancer and bone metastasis. New York: Plenum Press; 1992. p. 173-82.
7. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-83.
8. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-16.
9. Roudier MP, True LD, Higano CS, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003;34:646-53.
10. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
11. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.
12. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351:1488-90.
13. Tindall D, Horne FM, Hruszkewycz A, et al. Symposium on androgen action in prostate cancer. Cancer Res 2004;64:7178-80.
14. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy Nat Med 2004;10:33-9.
15. Gregory CW, Johnson RT, Jr., Mohler JL, et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61:2892-8.
16. Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004;91:13-25.
17. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-6.
18. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplifications possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314-9.
19. Linja MJ, Savinainen KJ, Saramaki OR, et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-5.
20. Latil A, Bieche I, Vidaud D, et al. Evaluation of androgen, estrogen (ER α and ER β), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001;61:1919-26.
21. Edwards J, Krishna NS, Grigor KM, et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89:552-6.
22. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27.
23. Makridakis N, Ross RK, Pike MC, et al. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res 1997;57:1020-2.
24. Labrie F, Dupont A, Belanger A, et al. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev 1986;7:67-74.
25. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001-15.
26. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004;91:483-90.
27. Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989;14:103-15.
28. Veldscholte J, Berrevoets CA, Ris-Stalpers C, et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992;41:665-9.
29. Zhao XY, Malloy PJ, Krishnan AV, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000;6:703-6.
30. Buchanan G, Greenberg NM, Scher HI, et al. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001;7:1273-81.
31. Shi XB, Ma AH, Xia L, et al. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 2002;62:1496-502.
32. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-8.
33. Tilley WD, Buchanan G, Hickey TE, et al. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996;2:277-85.
34. Marcelli M, Ittmann M, Mariani S, et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000;60:944-9.
35. Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003;21:2673-8.
36. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-8.
37. Culig Z, Steiner H, Bartsch G, et al. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005;95:497-505.
38. Craft N, Shostak Y, Carey M, et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-5.
39. Gioeli D, Ficarro SB, Kwiek JJ, et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 2002;277:29304-14.
40. Pienta KJ, Loberg R. The "emigration, migration, and immigration" of prostate cancer. Clin Prostate Cancer 2005;4:24-30.
41. Loberg RD, Logothetis CJ, Keller ET, et al. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 2005;23:8232-41.
42. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989;8:98-101.
43. Janne OA, Moilanen AM, Poukka H, et al. Androgen-receptor-interacting nuclear proteins. Biochem Soc Trans 2000;28:401-5.
44. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315-9.
45. Li P, Yu X, Ge K, et al. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 2002;161:1467-74.
46. Kang Z, Janne OA, Palvimo JJ. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 2004;18:2633-48.
47. Wang L, Hsu CL, Chang C. Androgen receptor corepressors: an overview. Prostate 2005;63:117-30.
48. Fujimoto N, Yeh S, Kang HY, et al. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 1999;274:8316-21.
49. Ngan ES, Hashimoto Y, Ma ZQ, et al. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene 2003;22:734-9.
50. Debes JD, Sebo TJ, Lohse CM, et al. p300 in prostate cancer proliferation and progression. Cancer Res 2003;63:7638-40.
51. Comuzzi B, Lambrinidis L, Rogatsch H, et al. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and antiandrogen-induced androgen receptor function. Am J Pathol 2003;162:233-41.
52. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-61.
53. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
54. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400.
55. Raffo AJ, Perlman H, Chen MW, et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-45.
56. Furuya Y, Krajewski S, Epstein JI, et al. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996;2:389-98.
57. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-51.
58. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 2005;55:300-18.
59. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
60. Tolcher AW, Chi K, Kuhn J, et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxet in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005;11:3854-61.
61. Xu L, Yang D, Wang S, et al. (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther 2005;4:197-205.
62. Gleave M, Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol 2005;23:38-46.
63. Beer TM, Eilers KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003;21:123-8.
64. McCarty MF. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Ther 2004;3:349-80.
65. Trump DL, Hershberger PA, Bernardi RJ, et al. Antitumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 2004;89-90:519-26.
66. Strother JM, Beer TM, Dreicer R. Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005? Eur J Cancer 2005;41:954-64.
67. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315:971-9.
68. Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology 2005;19:7-16.
69. Jimeno A, Carducci M. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther 2005;5:419-27.
70. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61.
71. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93.
72. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-87.
73. Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharmacokinetic- pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005;11:3385-91.
74. Eder IE, Culig Z, Ramoner R, et al. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 2000;7:997-1007.
75. O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17α-hydroxylase/C(17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317-25.
76. Chang CY, Abdo J, Hartney T, et al. Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. Mol Endocrinol 2005;19:2478-90.
77. Hewitson KS, Schofield CJ. The HIF pathway as a therapeutic target. Drug Discov Today 2004;9:704-11.
78. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004;91:1420-4.
79. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005;65:2825-31.
80. Mabjeesh NJ, Post DE, Willard MT, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002;62:2478-82.
81. Vanaja DK, Mitchell SH, Toft DO, et al. Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 2002;7:55-64.
82. Sakowicz R, Finer JT, Beraud C, et al. Antitumor activity of a kinesin inhibitor. Cancer Res 2004;64:3276-80.
83. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165-70.
84. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005;5:21-8.
85. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82.
86. Winquist E, Berry S. Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2004;96:1183.
87. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-13.
88. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004;63:940-5.
89. Bander NH, Milowsky MI, Nanus D, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23:4591-601.
90. Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 2004;60:197-204.
91. Nelson WG, Simons JW, Mikhak B, et al. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol 2000;46 Suppl:S67-72.
92. Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22:2122-32.